Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs NNI-362 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Neuronascent
- 05 Sep 2019 Status changed from planning to recruiting.
- 24 Sep 2018 New trial record
- 19 Sep 2018 According to a Neuronascent media release, the National Institute on Aging (NIA), part of the National Institutes of Health, has awarded the company an 18-month R01 award totalling about $2.25 million which will be used to support this trial.